Sravathi AI Technology Pvt Ltd was founded in 2020 and is headquartered in Bengaluru, India. It positions itself as an AI drug discovery and chemical innovation company. Its services target industries including pharmaceuticals, agrochemicals, specialty chemicals, peptides, and personal care. The core goal is to use AI to shorten traditional drug discovery and chemical process development cycles, while working in synergy with its sister companies in flow chemistry, microreactors, and continuous manufacturing to connect discovery through delivery.
Its platform portfolio leans more toward specialized R&D services than general-purpose AI tools. On the drug discovery side, it uses generative AI, predictive AI, molecular dynamics, quantum chemistry, and physics-based models to support target identification and validation, crystal structure prediction, pocket identification, small-molecule/peptide design, hit-to-lead optimization, drug repositioning, PROTAC, molecular glue, and ADC payload/linker design. The website also states that it can perform in silico analysis across 100+ properties and metrics, covering screening parameters such as physicochemical properties, ADMET, and pharmacokinetics.
On the chemistry AI side, it emphasizes a rule-driven plus data-driven platform. Capabilities include AI-based retrosynthetic route design, optimization of commercially available starting materials, shortest-route identification, non-infringing route development, impurity prediction, toxicophore and AMES risk assessment, yield optimization, catalyst/solvent/reagent selection, as well as design of solvent purification, recrystallization, and separation methods.
The website does not disclose pricing, plans, free trials, API access, or a self-service platform login, so it appears to be closer to project-based or enterprise R&D services. For teams that need a quick hands-on trial, transparency is limited. However, for pharmaceutical or chemical companies with a clearly defined target, compound series, or process challenge, a customized collaboration may be a better fit.
Its strengths lie in the breadth of the workflow it covers: it can connect AI molecular design, property prediction, quantum chemistry, route design, and process scale-up. This makes it especially suitable for early-stage candidate screening and reducing costs in chemical development. Its focus areas such as PROTAC, molecular glues, ADCs, and impurity prediction are also closely aligned with industry needs.
The limitations are that public materials lack model performance benchmarks, experimental validation data, detailed customer case studies, data privacy and intellectual property terms, and any indication of a Chinese interface or localization support. AI outputs should still be treated as computational decision support: candidate molecules, synthetic routes, and process conditions must be validated experimentally.
It is best suited for pharmaceutical R&D companies, API/intermediate manufacturers, agrochemical and specialty chemical companies, as well as research institutions with computational chemistry and process development needs. Access from China is unknown, and payment methods are not disclosed. If you are looking for alternatives or complementary solutions in China, it may be worth comparing with SchrΓΆdinger, Insilico Medicine, Exscientia, Atomwise, as well as domestic AI drug discovery platforms such as XtalPi and Insilico Medicine China.
β This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on sravathi.ai official site.
sravathi.ai is an Unknown AI Apps provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Workable. Click "Visit Official Site" to reach sravathi.ai directly.